Creative Medical Technology Reports IRB Approval for Phase ½ Clinical Trial of Novel Cell Therapy to Treat Type 1 Diabetes

Creative Medical Technology Reports IRB Approval for Phase ½ Clinical Trial of Novel Cell Therapy to Treat Type 1 Diabetes

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) reported that it has received Institutional Review Board approval to proceed with its clinical trial to treat Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. FDA had previously cleared the Company’s...